Tune Therapeutics key facts
as of Oct 2026- Developer of an epigenetic programming platform designed to create new pathways for the treatment of disease.
- Tune Therapeutics is valued at approximately $340.0M as of Oct 2026 (last reported valuation).
- It has raised $222.4M; the latest was Later Stage VC ($182.4M) in Jan 2025.
- Notable investors include New Enterprise Associates, Emerson Collective, Duke Capital Partners, Hatteras Venture Partners, Mission BioCapital — 15 tracked in total.
- Status: Privately Held (backing).
Tune Therapeutics's last reported valuation, Jan 2025. Nothing priced has surfaced since.
- ·The complete investor list: 15 names
- ·Watch Tune Therapeutics: the Monday email on marks, rounds and moves
Tune Therapeutics funding rounds
No funding rounds for Tune Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Tune Therapeutics
15+Tune Therapeutics valuation
Tune Therapeutics's last reported valuation was $340 million in Jan 2025. No priced round, secondary trade or fund mark has surfaced since.
Tune Therapeutics investors
15 investors are on record for Tune Therapeutics, including New Enterprise Associates, Emerson Collective, Duke Capital Partners and Hatteras Venture Partners.
About Tune Therapeutics
Developer of an epigenetic programming platform designed to create new pathways for the treatment of disease. The company's platform helps to develop paradigm-changing cell and gene therapies that leverage epigenetic programming for the treatment of devastating diseases by tapping into the epigenome to program biology without altering the deoxyribonucleic acid sequence, enabling patients with treatments for pervasive diseases.
- Sector
- Healthcare
- HQ
- Durham, NC, United States
- Founded
- 2020
- Employees
- 75
- Website
- tunetx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.